SCHEMBL23099307

SCHEMBL23099307

O=Cc1cccc(Oc2ccccc2NC(=O)CNC(=O)c2cccc3ccccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ MTNR1B P49286 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.43
▸ BRAF P15056 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ADRA2C P18825 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SENP1 Q9P0U3 1/20 0.41
▸ TAOK1 Q7L7X3 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21675770 0.90 ALDH1A1 (0.45) KDM4EMEN1KMT2AALDH1A1ADRA2C
SCHEMBL29660113 0.88 ADRA2C (0.54) MEN1KMT2AMTNR1BALDH1A1RAB9A
SCHEMBL18666146 0.88 ADRA2C (0.54) MEN1KMT2AMTNR1BALDH1A1RAB9A
SCHEMBL18666150 0.87 MTNR1B (0.47) KDM4EMAPTMTNR1BALDH1A1BRAF
SCHEMBL18666151 0.86 MTNR1B (0.63) KDM4EMEN1MAPTKMT2AMTNR1B
SCHEMBL30567101 0.86 MTNR1B (0.63) KDM4EMEN1MAPTKMT2AMTNR1B
SCHEMBL31120716 0.83 MTNR1B (0.47) MTNR1BALDH1A1BRAFADRA2CGAA
SCHEMBL18666199 0.83 DEGS1 (0.49) KDM4EMEN1KMT2AALDH1A1ADRA2C
SCHEMBL18666157 0.82 ALDH1A1 (0.48) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL18666149 0.82 ALDH1A1 (0.55) KDM4EMEN1MAPTKMT2AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345656-B2 PCNA inhibitors CITY OF HOPE (US) 2022-05-31 — — US disclosed
US-20210078938-A1 PCNA INHIBITORS THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY 2021-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078938-A1 PCNA INHIBITORS PCNA, MKI67, PCLAF KDM4E 2125/4885MEN1 2671/4885MAPT 3403/4885
US-11345656-B2 PCNA inhibitors PCNA, MKI67, PCLAF KDM4E 2125/4885MEN1 2671/4885MAPT 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback